Africa & Middle East

Kenya’s 2026–2030 Health Products and Technologies Local Manufacturing Strategy targets local production of at least 50 per cent of the country’s essential health products.

Construction was completed in 2013 at a reported cost of nearly Sh200 million (US$1.54 million) through donor funding from the UAE-based Dar Al Ber Society.

The hospital, part of Aster DM Healthcare, also ranked second in the UAE and 253rd globally for Cardiology in Newsweek’s World’s Best Specialized Hospitals 2027.

The Pediatric Private Home Visits: Wellness and Vaccinations program covers routine services that support children’s health and development.

The company has developed an integrated value chain around cinchona cultivation, quinine production and pharmaceutical manufacturing, with malaria treatment forming an important part of its activities.

The facility adds domestic manufacturing capacity to the company’s operations as Kenya seeks to strengthen production of medical products within the country.

The DIGIT platform is designed as an open and interoperable system that brings campaign planning, management and monitoring into a single interface.

The intervention was guided by Transesophageal Echocardiography (TEE) and the Cath Lab’s image intensifier system.

The AD BMT® program at Yas Clinic Khalifa City and ADSCC manages pediatric and adult cases requiring specialized transplantation, including immune disorders, rare genetic diseases and other high risk conditions.

The assessment identified strengths and areas for improvement, while the technical sessions gave EFDA experts practical experience relevant to meeting WHO requirements.